Innovative Rescue Devices Crossject has developed the needle-free autoinjector ZENEO and is actively advancing its ZEPIZURE product line for emergency therapies such as epilepsy and allergic reactions. This focus on innovative, easy-to-use rescue devices presents significant sales opportunities with hospitals, emergency response teams, and healthcare providers seeking patient-friendly solutions.

Strategic Funding & Partnerships recent funding rounds and strategic partnerships, including collaborations with Heights Capital and government contracts like BARDA, indicate strong financial backing and growth potential. These avenues can facilitate expansion into new markets and foster relationships with organizations interested in cutting-edge medical devices.

Expanding Market Presence Crossject's operations in both France and the U.S., coupled with its recent successful funding efforts, position it well to explore international sales channels, especially targeting countries with burgeoning pharmaceutical and emergency medical device markets looking for needle-free injection solutions.

Focus on Emergency Therapies With a product pipeline centered around rescue therapies for severe allergic reactions, opioid overdoses, and asthma attacks, sales opportunities exist within hospitals, ambulatory care, and emergency services that require rapid, reliable, and user-friendly medication delivery systems.

Technology & User Engagement Crossject’s emphasis on needle-free, easy-to-use autoinjectors that can be administered by untrained caregivers enhances its appeal to organizations prioritizing patient safety, compliance, and convenience—key factors for driving sales across clinical and non-clinical settings.